Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
King, A.J., Patrick, D.R., Batorsky, R.S., Ho, M.L., Do, H.T., Zhang, S.Y., Kumar, R., Rusnak, D.W., Takle, A.K., Wilson, D.M., Hugger, E., Wang, L., Karreth, F., Lougheed, J.C., Lee, J., Chau, D., Stout, T.J., May, E.W., Rominger, C.M., Schaber, M.D., Luo, L., Lakdawala, A.S., Adams, J.L., Contractor, R.G., Smalley, K.S., Herlyn, M., Morrissey, M.M., Tuveson, D.A., Huang, P.S.(2006) Cancer Res 66: 11100-11105
- PubMed: 17145850 
- DOI: https://doi.org/10.1158/0008-5472.CAN-06-2554
- Primary Citation of Related Structures:  
2FB8 - PubMed Abstract: 
Oncogenic BRAF alleles are both necessary and sufficient for cellular transformation, suggesting that chemical inhibition of the activated mutant protein kinase may reverse the tumor phenotype. Here, we report the characterization of SB-590885, a novel triarylimidazole that selectively inhibits Raf kinases with more potency towards B-Raf than c-Raf ...